We serve Chemical Name:3-ethynyloxetan-3-ol CAS:1352492-38-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-ethynyloxetan-3-ol
CAS.NO:1352492-38-6
Synonyms:3-ethynyloxetan-3-ol
Molecular Formula:C5H6O2
Molecular Weight:98.09990
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:29.46000
Exact Mass:98.03680
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-ethynyloxetan-3-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-ethynyloxetan-3-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-ethynyloxetan-3-ol Use and application,3-ethynyloxetan-3-ol technical grade,usp/ep/jp grade.
Related News: Indonesia is suspending its visa-free travel for Chinese citizens and barring passengers who have visited mainland China in the past 14 days. 3-ethynyloxetan-3-ol manufacturer Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control. 3-ethynyloxetan-3-ol supplier Indonesia is suspending its visa-free travel for Chinese citizens and barring passengers who have visited mainland China in the past 14 days. 3-ethynyloxetan-3-ol vendor It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. 3-ethynyloxetan-3-ol factory The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.
